improving outcomes for australians with lung disease · 2018. 9. 11. · improving outcomes for...

Freecall 1800 654 301 lungfoundation.com.au of 18

Improving outcomes for Australians

with lung disease

Submission for the 2018-19 Federal Budget

from Lung Foundation Australia


Introduction

Lung disease has a major impact in Australia, both in terms of healthcare utilisation and lost quality of life for

patients and carers. Lung disease contributes more than 10% to the overall health burden in Australia (1).

When we consider the impact on Aboriginal and Torres Strait Islander populations and Australians living in

regional, rural and remote areas across Australia, this burden is even greater (2) (3).

For people living with lung disease in Australia (1):

Lung cancer represents the leading cause of death (40% of deaths from lung disease)

Chronic Obstructive Pulmonary Disease (COPD) contributes to one-third (1/3) of the overall health

burden and to almost 1/3 of all respiratory deaths

Lower respiratory infections are the leading cause of hospital admission

Asthma represents the leading cause of disability

Over the past 15 years, the Commonwealth has taken a national strategic approach to improving outcomes in

one lung disease – asthma. This strategic approach, along with sustained investment in research, clinical and

community education & support, has driven a dramatic reduction in hospitalisations and asthma deaths in

Australia. Equally beneficial outcomes can be expected if a similar investment were implemented in other,

higher impact lung diseases such as chronic obstructive pulmonary disease (COPD), lung cancer, Idiopathic

Pulmonary Fibrosis (IPF) and respiratory infection.

It is important to acknowledge gains made by government in tobacco control, the establishment of the

Medical Research Future Fund (MRFF) and recent access to life changing medications for those with IPF and

lung cancer.

Despite these positive developments, lung disease still does not receive the funding and support warranted by

its outcomes and relative to its burden.

This submission outlines a number of high priority, cost-effective actions that will lead to better outcomes for

patients, including support for: timely and accurate diagnosis; a reduction in preventable hospitalisations;

improvements in the capacity of patients and carers to take an active role in managing their condition; and

life-changing research.

Lung Disease in Australia – The key facts that need to change

COPD is the second leading cause of potentially preventable hospitalisations (PPHs) – responsible for

10% of all PPHs (3)

o Compared with the OECD average of 198 COPD hospital admissions per 100,000 people,

Australia experienced 305 COPD hospital admissions per 100,000 people in 2013, putting

Australia fourth from the bottom of 34 OECD countries. (4)

o The rate of potentially preventable hospitalisation for COPD was 5 times higher for Aboriginal

and Torres Strait Islander Australians than other Australians (3)

Lung cancer is the biggest cancer killer in Australia, killing more people than breast, ovarian and

prostate cancers combined (5)

o Indigenous Australians are 1.7 times more likely to develop lung cancer and twice as likely to

die from lung cancer than non-indigenous Australians (6)

o There is unacceptable variation in the care received by patients with lung disease between

local areas (3)


Acute respiratory infection caused 130,000 hospitalisations in 2011/12 (1.4% of all hospitalisations) and

3,000 deaths in 2012 (2.1% of all deaths in Australia in that year) (1). In 2017 there was an unexpected

high rate of influenza related illness and hospital admissions. Many are preventable.

o Respiratory tract infections are a major health burden leading to school, work and productivity

loss (7).

Alignment with Government Strategy

The recommendations outlined in this submission align with current government policy and strategy,

specifically:

The Australian Commission on Safety and Quality in Healthcare, in its Second Atlas of Healthcare Variation

(2017), reported that the lack of adherence to best practice in primary care contributes to variation in

hospitalisation and health care costs by leading to differences in patient education for effective self-

management, rates of influenza and pneumonia vaccination, smoking cessation uptake, delayed diagnosis and

late access to care. The Commission recommends: “Earlier diagnosis through greater use of spirometry in

primary care, strong care coordination and improved access to pulmonary rehabilitation could substantially

improve outcomes for people with COPD in Australia.” (3)

The Senate Select Committee into Funding for Research into Cancers with Low Survival Rates (LSR) (2017)

recommends:

Make low survival rate cancers (including lung cancer) a National Health Priority Area

Implement awareness activities to reduce the amount of time to detect and diagnose LSR cancers

Improve awareness of LSR cancers amongst general practitioners

Improve access to specialist cancer care coordinators or nurses for LSR cancers

National Strategic Framework for Chronic Conditions (2017) Strategic Priority areas identified include:

Promote health and reduce risk

Timely and appropriate detection and intervention

Continuity of care

Partnerships for health.


Cost Effective Interventions

This submission identified opportunities to change the face of lung disease in Australia. The opportunities

have been selected because of the effectiveness of each and where an evidence base supports national

implementation.

Intervention Cost

1. Widen access to pulmonary rehabilitation Overall savings to the sector through prevented

hospitalisations and reduced length of stay

2. Facilitate earlier detection and diagnosis of

lung disease through awareness, primary

care education and appropriate

reimbursement for spirometry testing at

primary care

Awareness: $5M over 3 years

GP education: $200,000 one off development costs

Spirometry reimbursement: MBS fee

3. Increase capacity of primary care sector to

manage chronic lung disease by scaling up

existing national training initiatives

$5M over 3 years

4. Provide funding for Specialist Lung Cancer

Nurses (SLCNs)

$8M to implement a two year pilot program and

evaluation

5. Support chronic lung disease patients and

their carers to self-manage through

provision of national COACH program

$1.2M over 3 years

6. Redress research funding gap for lung

disease to reflect the burden of disease

$8.1M over 3 years


What is pulmonary rehabilitation? Comprehensive 8 week EXERCISE and EDUCATION

program provided by specially trained health professionals

Teaches people with lung disease the skills that they need to know to stay well and out of hospital: o How to manage breathlessness so they are not over-

using medicines o How to coordinate breathing with movement so they

can resume activities of daily life o How to clear lung secretions to reduce infections o How to cope with anxiety, depression and panic

attacks o Other education: medications, social services, diet,

intimacy

1. Widen Access to Pulmonary Rehabilitation

Chronic lung diseases, such as chronic obstructive pulmonary disease (COPD), bronchiectasis, IPF and lung

cancer cause breathlessness which decreases a person’s ability to perform daily activities, affects quality of life

and results in increasing morbidity. COPD is the second leading cause of preventable hospitalisations (8).

The most effective evidence-based

intervention to manage breathlessness in

chronic lung diseases is non-

pharmacological. It is pulmonary

rehabilitation. If COPD were optimally

managed in primary care, a proportion of

costly hospital admissions could be

avoided by promoting physical activity for

people with COPD. Pulmonary

rehabilitation is a key component of

optimal management as cited in the

Australian Guidelines for the

Management of COPD. (9)

In patients with COPD and other chronic

lung diseases, pulmonary rehabilitation

improves quality of life, increases

exercise capacity, and reduces symptoms,

mortality, hospitalisations/readmissions

and in-patient bed days (9).Two

Australian randomised controlled trials

demonstrated a minimum of 20% reduction in COPD hospital admissions (10) (11).

Pulmonary rehabilitation is cost effective (12) and can safely be delivered in the community for most patients.

Available data suggest that access to pulmonary rehabilitation programs in Australia is extremely limited (13).

The Australian Institute of Health & Welfare (AIHW) states that: “…it appears that many, and possibly the

majority, of patients with COPD who could benefit from pulmonary rehabilitation do not receive this service.

The reasons include availability of local programs, transport, waiting periods, referral patterns and practitioner

and patient choice.” (14)

Lung Foundation Australia currently has an

application for a Medical Benefits Scheme (MBS)

item number for the delivery of pulmonary

rehabilitation in the community. It is scheduled to

be considered by the Medical Services Advisory

Committee (MSAC) in October 2018. If successful,

additional pulmonary rehabilitation programs would

be established in the community, increasing access

and choice for patients. An overall cost saving

would be predicted since the costs of an MBS item

number for pulmonary rehabilitation would be

offset by reduced healthcare costs and hospital

admissions for COPD and other chronic lung

diseases.


Given the potential for this intervention to reduce hospitalisations from chronic lung disease, we recommend

immediate approval of this application.

Recommendation: Approve Application 1405 to MSAC which would provide an MBS item number for the

delivery of pulmonary rehabilitation in the community.

Cost: Expected overall saving to the sector as cost of delivery would be offset by reduced healthcare costs and

hospital admissions.


2. Facilitate earlier diagnosis of lung disease through awareness, GP education and

national spirometry plan

Awareness and GP education: Lung disease is often diagnosed late through lack of awareness of symptoms

and lack of urgency about symptoms.

Symptoms of lung disease include

shortness of breath, cough, chest pain,

haemoptysis, all of which can be

attributed to different causes and

lifestyle choices.

Cough is one of the most common

presentations to general practice, yet

there is currently no national training

available focusing on cough and other

symptoms of lung disease (15).

Diagnosis of COPD is often not

confirmed until symptoms are

significant and well progressed. In

fact, half of the people with symptoms

don’t have a confirmed diagnosis (16)

and are therefore not taking the

important steps that can improve their

health and prevent increasing disability.

Lung cancer is often confirmed late, often following emergency presentation, as symptoms of cough and

breathlessness are ignored. Persistent symptoms, especially in people with risk factors, must be

urgently investigated. Australian guidelines state that a cough lasting for three weeks should prompt

further investigation (17) (18).

Lung disease is so closely associated with smoking that there is a lack of awareness of other risk factors

(genetic, occupational), and symptoms in smokers are frequently dismissed, and symptoms in smokers

are frequently dismissed (19)

Rarer lung diseases, such as idiopathic pulmonary fibrosis and pulmonary arterial hypertension, are

particularly challenging, but may present with identical symptoms, such as chest tightness and

breathlessness.

Early and accurate diagnosis is required to institute early treatment and management, avoid inappropriate

prescribing, and to prevent avoidable healthcare costs and resource utilisation (20).

A national awareness campaign, including primary care education, would:

Increase understanding that lung disease can affect anyone, not just current smokers

Improve knowledge of occupational risks of lung disease

Enhance understanding of symptoms (cough of three weeks, shortness of breath, chest pain) of lung

disease and urgency to act

Ensure primary care practitioners know the appropriate referral pathways and urgency for referral


In the UK, a National Health Service campaign, “Be Clear on Cancer”, focusing on respiratory symptoms,

showed that 700 more lung cancer cases were diagnosed during the campaign period compared to a similar

period the previous year. It also showed diagnoses happened at an earlier stage - 400 more people had their

cancers diagnosed at an earlier stage and 300 additional patients had surgery as a first treatment for

diagnosed lung cancer which gives them the best chance of prolonged survival. The campaign also resulted in

an increase in two week referrals for suspected lung cancer of 30%. Spontaneous recognition of

breathlessness as a symptom of lung disease and heart disease increased 50% and 42% respectively (21). The

campaign has been repeated three times, the third time combining breathlessness and cough to increase

earlier diagnosis of both lung cancer and COPD.

A national awareness campaign in Australia focusing on cough and breathlessness would aim to increase

recognition of important symptoms of lung disease and drive those with symptoms to speak to their doctor.

The campaign would include supporting primary care education (on-line education module focusing on

symptom recognition, a systems approach to identifying those at high risk of lung disease; and information on

appropriate referral pathways).

Appropriate payment for spirometry testing at primary care: Earlier diagnosis is not only a result of lack of

awareness. A further barrier to timely diagnosis of lung disease is the lack of routine assessments and testing

of those at risk of lung disease in the primary care setting. This means that people are missing out on the

opportunity for earlier diagnosis and, therefore, earlier treatment and management. Amongst primary care

practitioners, studies show that spirometry testing (essential to making a diagnosis of airways disease (9)) is

not consistently done to confirm a diagnosis (22).

This lack of confirmation of airways disease through spirometry, results in delayed management and

inappropriate prescribing.

An Australian study of COPD patients seen by a general practitioner found that 50% of them were diagnosed

without spirometry testing and 65% of patients with COPD were diagnosed on presentation to hospital with an

exacerbation (23). A further study identified that 82% of study participants were initiated on medicine

without a lung function test performed within 12 months, either before or after their initial prescription (24).

This is confirmed by MBS data.

There are practical barriers to the performance of spirometry in primary care. These predominantly relate to

the inadequate reimbursement for spirometry, given the cost of equipment and time taken to perform the

tests.

The recent national Thoracic Medicine and Sleep Clinical Committee for the MBS review included

consideration of remuneration for spirometry testing at primary care. A recommendation to increase

payment to better reflect the time and skill required to conduct quality spirometry was made by the review

committee. The federal government should accept this recommendation and rapidly implement it.

Recommendation: Implement a national program to promote early diagnosis of lung disease including:

development of online primary care education on symptoms and referral pathways for lung disease;

community awareness campaign highlighting symptoms and risk factors for lung disease; and increased

reimbursement for spirometry conducted at primary care (as recommended by the recent MBS review on

spirometric testing).

Cost: $5.2M over three years + MBS item cost. Savings are difficult to predict but we could expect to see a

savings in PBS and MBS payments from avoidance of unnecessary treatment, lower adverse effects of

treatment, accurate diagnosis leading to more appropriate referral for treatment and lifestyle changes.


3. Increase capacity of primary care to manage chronic lung disease by scaling up

existing national training initiatives

Most chronic lung disease, particularly COPD, can and should be managed by primary care.

In Australia, COPD is a leading cause of mortality and morbidity. Compared to OECD countries, COPD is poorly

managed in Australia, leading to higher rates of potentially preventable hospital admissions (4). In fact,

compared to the OECD, Australia has one of the highest rates of potentially avoidable hospitalisations for

COPD (4).

There is poor uptake and delivery of COPD Guidelines aligned management, including (25):

1. Promotion of physical activity and referral to pulmonary rehabilitation

2. Development of an agreed action plan, in partnership with patients

3. Medication and device technique training for patients with regular review

4. Adult vaccination, including influenza and pneumococcal and promotion of interventions that reduce

infection transmission to vulnerable people

5. Recognition of factors predisposing people to pneumonia and when to use and not to use antibiotics

6. Promotion of the important role of patient self-management.

Wide variation of care for COPD contributes to morbidity and mortality: The Australian Commission on

Safety and Quality in Healthcare, in its Second Atlas of Healthcare Variation, reported that the lack of

adherence to best practice in primary care contributes to variation in hospitalisation and health care costs,

leading to differences in patient education for effective self-management, rates of influenza and pneumonia

vaccination, smoking cessation uptake, delayed diagnosis and late access to care. Variation of care for COPD

was found to be the worst amongst the five chronic diseases driving the bulk of hospitalisations in Australia.

When measuring Guideline-recommended care delivery for COPD, a massive 16-fold difference was observed

between local areas. The Commission recommends: “Earlier diagnosis through greater use of spirometry in

primary care, strong care coordination and improved access to pulmonary rehabilitation could substantially

improve outcomes for people with COPD in Australia.” (3)

More training opportunities need to be offered to build the capacity of primary healthcare professionals in the

identification diagnosis and management of patients with COPD and asthma-COPD overlap.

Lung Foundation Australia has a proven program and track record in delivering education to primary care

professionals through a network of trained and expert clinicians. In building workforce capacity we focus on

collaboration and already work with several key partners in this space, including Australian College of Rural

and Remote Medicine, Pharmaceutical Society Australia and Australian Practice Nurses Association, on COPD

training initiatives. An investment into this already established infrastructure and training resources would

widen the reach of this program, particularly into regional, rural and remote settings.

Recommendation: Invest in growing the existing and proven primary healthcare professional training program

that supports general practitioners and other primary healthcare professionals to implement evidence-based

COPD Guidelines management to ensure patients are empowered to self-manage (with a particular focus on

rural and remote health care professionals).

Cost: $5Million over three years.


4. Provide funding for specialist lung cancer nurses (SLCNs)

Lung cancer is the biggest cancer killer in Australia. It accounts for more cancer deaths than breast, ovarian

and prostate cancers combined (5). In 2016, more than 12,000 Australians were diagnosed with lung cancer

and almost 9,000 lost their lives to the

disease (26)). This is equivalent to

approximately 25 deaths per day from lung

cancer. The incidence of lung cancer in

Australia continues to increase in males and

females and the prognosis for those

diagnosed remains poor (26). The 5-year

relative survival from lung cancer remains

low at 15% (6). For those diagnosed with

lung cancer at an advanced stage, the 5-

year relative survival is only 1% (6), or a 1 in

100 chance of surviving 5 years from

diagnosis. These figures for 5-year relative

survival are significantly lower than for

other frequently diagnosed cancers, for

example, prostate cancer (6).

Evidence indicates that lung cancer patients

experience higher symptom distress and experience more psychological distress and report a higher number

of unmet supportive care needs than patients with other types of cancer (27) (28) (29). Stigmatisation

experienced by lung cancer patients (27) (28) further exacerbates psychological distress placing them at a

higher risk of suicide compared to people with other cancer types (30). It is perhaps unsurprising that people

living with lung cancer report a lower quality of life than people living with other cancer types (32) (33).

One of the key challenges for lung cancer patients is that in presenting to a primary care setting, they may be

delayed in their referral to a specialised lung cancer multidisciplinary team (MDT) (29). Several factors can

explain this, including: lack of awareness of relevant symptoms and lack of sense of urgency about symptoms;

varying levels of awareness about the appropriate referral pathway; a belief that lung cancer only occurs in

smokers; gaps in the coordination of a complex diagnostic pathway; perceived nihilism of some referring

doctors and other clinicians; and limited sharing of information from multiple providers across different

information platforms (30).

Despite the demonstrated personal, social and economic impacts of lung cancer in Australia and the systemic

challenges that exist around the lung cancer pathway, there is minimal supportive care for those diagnosed

with lung cancer.

Evidence suggests that Specialised Lung Cancer Nurses (SLCNs) are well placed to address the gaps and

barriers and challenges faced by people at all stages in the lung cancer trajectory (ref). In the UK, for example,

the SLCN role has been shown to be a catalyst in patient access to treatment, including assessment, managing

symptoms, psychosocial support, and information provision. (31)

The Clinical Practice Guidelines for the Treatment of Lung Cancer, commissioned by Cancer Australia, state that

best practice lung cancer treatment and care is delivered by an MDT, of which the SLCN is cited as a core

member. Moreover, the Guidelines state that the SLCN is the health professional recognised as being the one

constant health professional for lung cancer patients across their disease journey. SLCNs ensure patients’

needs and preferences are addressed from pre-diagnosis through to end of life.


In the UK, the National Health Service (NHS) is aiming to provide lung cancer nurses to meet the needs of 90%

patients at diagnosis. They already reach over 70% patients. The role of the SLCN is critical to coordinate and

optimise care for patients, as well as to provide them with clinical, social and emotional support (30).

Cancer Australia’s Clinical Practice Guidelines for the Treatment of Lung Cancer: Including a LCN in the care

of patients from early in the diagnosis-decision making stage may be highly valuable.

By extension of the universal acceptance of the role of breast care nurses, it seems more than probable that

patients with lung cancer would benefit in a similar fashion (30).

The recently released Senate Report into Low Survival Rate Cancers recommends : The committee

recommends that the Australian government, in conjunction with its state and territory counterparts, works to

improve access to specialist cancer care coordinators or nurses for low survival rate cancer patients in every

state and territory (32).

There is a critical shortage of SLCNs in Australia. Currently, the funding model for the role is driven at the

hospital or clinic level resulting in diversity in the way the role is implemented that does not necessarily

associate with optimal patient care. Clinical Practice Guidelines (30) recommend there should be at least one

SLCN per MDT. There are currently 66 MDTs in Australia and there are 29 SLCNs positioned in teams across

Australia. This situates the delivery of lung cancer care well short of best practice.

Most of these 29 nurses are employed in a part-time or half-time capacity, equating to approximately 8 full

time equivalent (FTE) positions. Data by Cancer Australia report 12,434 new lung cancer cases were identified

in 2017 (26). This means there was an estimated one SLCN for every 1,500 new patients each year. This

compares poorly to the UK ratio of one SLCN to every 100-200 patients (33).

Recommendation: Provide funding to ensure a SLCN or oncology nurse is associated with each of the 66 Lung

Cancer MDTs in Australia.

Cost: $8Million to support a two year pilot program to position SLCNs in lung cancer MDTs. This funding

would enable rigorous independent evaluation and the opportunity to fine-tune the program. Key drivers

include sustainability of the program and assurance that cost savings can be reinvested in services


5. Support patients and their carers to self-manage through the provision of a

national COACH program

The important role of self-management for those with chronic disease is well documented. Self-management

interventions in patients with COPD are associated with improved health-related quality of life, a reduction in

respiratory-related and all cause hospital admissions, and improvement in breathlessness (34).

Literature reports, however, that patients are not consistently receiving education and information on and

motivation about actions they can take to help self-manage their condition. Nor are they being referred

regularly to Lung Foundation Australia for support (see Box).

The patient experience – study by For Benefit Insights

The ‘Living with COPD Report’ was developed to gain a better understanding of patient experiences.

Information was drawn from seven focus groups comprising a total of 39 patients (mixture of mild, moderate

and severe COPD) in four locations. The findings of the study highlighted the need for earlier identification of

people at risk of COPD and improved self-management support from primary healthcare professionals. These

included:

Almost 80% of diagnoses were made by specialists or due to the patient presenting to hospital. These

people could have been identified and diagnosed in a primary care setting.

A poor explanation of COPD at diagnosis and an absence of resources such as printed information. There

was also a low knowledge of Lung Foundation resources. Patients could be referred to the Lung

Foundation to access evidence-based self-management material.

GPs were noted as the cornerstone of care but there was higher engagement from specialists in review of

patients including their medicines.

Low levels of inhaler device checks were conducted. Some patients had to learn proper technique by

reading the instructions provided with the medicine.

A national program designed to systematically refer

to and provide coaching support will support

patients to take more control of their disease and

manage their symptoms, thus keeping them well,

enhancing quality of life, and staying out of hospital.

Targeting efforts to ensure those living in rural and

remote locations will go some way to reducing the

variation of care that those living outside the main

centres are able to access.

The Coach Program (www.thecoachprogram.com) is

an evidence-based program that has been shown to

help patients achieve better health outcomes. Lung

Foundation Australia recommends funding to

support the employment of a COPD nurse to pilot,

implement and evaluate the COACH Program

embedded into the support the Lung Foundation

already provides.

http://www.thecoachprogram.com/


Recommendation: Fund the provision of a national Coaching and self-management support program

embedded in Lung Foundation Australia. Pilot this program for patients with chronic lung disease, particularly

those with chronic obstructive pulmonary disease or pulmonary fibrosis.

Cost: $1.2Million to establish the Coaching program and pilot over three years.


6. Redress research funding gap for lung disease to reflect the burden of disease

Despite the significant burden of lung disease

(see Page 1) in Australia, research in lung

disease is significantly underfunded.

The National Health and Medical Research

Council (NHMRC) has allocated 5.3% of its

funding from 2012-2016 for respiratory

research (35). Lung disease accounts for

10.3% of the total burden of disease in

Australia (1).

Despite being the biggest cancer killer in

Australia, accounting for 20% of all cancer

deaths, in 2006-2011 lung cancer received

only 5% of tumour specific research funding

nationally (5).

This relative under-funding of research in lung

cancer and other lung diseases is a significant

barrier to attracting the brightest researchers

to work in lung cancer or other lung diseases

in Australia. This will have a serious negative

impact on the quality of research applications

into lung disease in the future, putting

Australia at risk of falling behind

internationally.

The Select Committee into Funding for Research into Cancers with Low Survival Rates (LSR) recommended

increasing research funding for LSR cancers (including lung cancer) by:

Having NHMRC identify LSR cancers a National Health Priority

Having NHMRC introduce options to extend existing funding to recipients of current grants (32)

Investment in lung disease research undoubtedly drives improvement in quality experiences and outcomes for

patients and which, in turn, contributes enormous social and economic benefits. Importantly, research

funding will support promising researchers to include lung disease research in their career plans.

Australian government funding for 20 mid-career research fellowships and 10 linked PhD fellowships will help

to future proof Australian research in lung disease and improve outcomes for patients.

Recommendation: Fund 20 mid-career research fellowships across the various lung diseases, with a priority

placed on those with highest burden, including lung cancer, COPD, Idiopathic Pulmonary Fibrosis, Respiratory

Infection and Bronchiectasis. It is also recommended that 10 PhD fellowships be linked to some of the mid-

career fellowships. Each three year mid-career fellowship would offer $80,000 per annum in salary plus

$40,000 annually for project support ($7.2M over three years). Each three year PhD fellowship would offer

$30,000 per annum in salary ($900,000). Total $8,100,000 over three years.


Lung Foundation Australia

Lung Foundation is the only national charity that represents anyone with a lung disease. The mission of the

Lung Foundation is to reduce the impact of lung disease in Australia through:

Promoting lung health

Promoting timely diagnosis of lung disease

Supporting those with lung disease and their carers

Promoting equitable access to evidence-based care

Driving quality research.

Contact:

Lung Foundation Australia

M: Level 2, 11 Finchley street, Milton, QLD 4064

P: 1800 654 301

W: lungfoundation.com.au


References

1. Poulos, Leanne M, et al., et al. Lung disease in Australia. Sydney : Woolcock Institute of Medical Research, 2014.

2. Australian Indigenous HealthInfoNet. Overview of Aboriginal and Torres Strait Islander Health status, 2016.

Perth, WA : Australian Indigenous HealthInfoNet, 2017.

3. Australian Commission on Safety and Quality in Healthcare and Australian Institute of Health and Welfare. The

Second Australian Atlas of Healthcare Variation. Sydney : ACSQHC, 2017. 978-1-925224-82-5.

4. OECD. Health at a Glance 2015: OECD Indicators. Paris : OECD Publishing, 2015.

5. Cancer Australia. Cancer Research in Australia: an overview of funding to cancer research projects and research

programs in Australia 2006 to 2011. Surry Hills, NSW : Cancer Australia, 2014. 978-1-74127-277-2.

6. Australian Institute of Health & Welfare and Cancer Australia. Cancer in Aboriginal and Torres Strait Islander

peoples of Australia: an overview. Canberra : Australian Institute of Health & Welfare, 2013.

7. Respiratory Infectious Diseases Group, Lung Foundation Australia. Respiratory Infectious Disease Burden in

Australia. Brisbane : Lung Foundation Australia, 2007.

8. Page A, Ambrose S, Glover J et al. Atlas of Avoidable Hospitalisations in Australia: ambulatory care-sensitive

conditions. Adelaide : University of Adelaide, Adelaide PHIDU, 2007.

9. Yang, I A, et al., et al. The COPD-X Plan: Australian and New Zealand Guidelines for the management of Chronic

Obstructive Pulmonary Disease 2017 Version 2.49. The COPD-X Plan. [Online] March 2017. [Cited: 15 July 2017.]

http://copdx.org.au/copd-x-plan/.

10. Home-based rehabilitation for COPD using minimal resources: a randomised, controlled equivalence trial.

Holland Anne E, et al. s.l. : Thorax, 2016, Vols. http://dx.doi.org/10.1136/thoraxjnl-2016-208514.

11. Reduction in hospitalisation following pulmonary rehabilitation in patients with COPD. Cecins N., et al. s.l. :

Australian Health Reveiw, 2008, Vol. Vol 32 No 3.

12. Griffiths, T., et al. Cost effectiveness of an outpatient multidisciplinary pulmonary rehabilitation. A randomised

controlled trial. s.l. : Thorax, 2001.

13. Australian Lung Foundation. The Australian Lung Foundation Market Research Report: Pulmonary Rehabilitation

Survey. Sydney : StollzNow Research, 2007.

14. Australian Institute of Health and Welfare, Marks G, Reddel H, Guevara-Rattray E, Poulos L and Ampon R.

Monitoring pulmonary rehabilitation and long-term oxygen therapy for people with chronic obstructive pulmonary

disease (COPD) in Australia: a discussion paper. Canberra : Australian Institute of Health and Welfare, 2013. 1-

74249-516-3.

15. General practice activity in Australia 2013-14. Britt, H et al. Sydney : General practice series no 36, 2014. 978-1-

74332-422-6.

16. Xuan, W, et al., et al. Prevalence of respiratory symptoms, illnesses and spirometric diagnoses in the Australian

BOLD study. Respirology. 16, 2011, Vol. 51.

17. Cancer Australia. Investigating symptoms of lung cancer: a guide for GPs. Sydney : Cancer Australia, 2012.

18. Cough in Children and Adults: Diagnosis and Assessment. Australian Cough Guidelines. Gibson, Peter et al. 271,

s.l. : Medical Journal of Australia, 2010, Vol. 265.


19. Pure Profile. Lung Cancer Consumer Survey [A-8554]. Brisbane : Lung Foundation Australia, 2017.

20. Jones RC., Price D., et al. Opportunities to diagnose chronic obstructive pulmonary disease in routine care in the

UK: a retrospective study of a clinical cohort. s.l. : The Lancet Respiratory Medicine, 2014.

21. UK, Cancer Research. Be Clear on Cancer. London : Cancer Research UK, Accessed Decembr 2017 at:

http://www.cancerresearchuk.org/health-professional/awareness-and-prevention/be-clear-on-cancer/lung-cancer-

campaign.

22. Toelle, B G, et al., et al. Respiratory symptoms and illness in older Australians: the Burden of Obstructive Lung

Disease (BOLD) study. Med J Aust. 2013, 198, pp. 144-8.

23. Walters J AE, et al. Barriers to the use of spirometry in general practice. s.l. : Australian Family Physician, Vol

34,3: 2005.

24. Poulos LM, et al. The use of lung function testing for the diagnosis and management of chronic airways disease.

Canberra : Australian Institute of Health and Welfare, 2016. 9778-1-76054-006-7.

25. Initial diagnosis and management of chronic obstructive pulmonary disease in Australia: views from the coal

face. Bereznicki, Bonnie et al. s.l. : Internal Medicine Journal, 2017.

26. Cancer Australia. Lung Cancer statistics. s.l. : https://lung-cancer.canceraustralia.gov.au/statistics, 2017.

27. Distress screening in a multidisciplinary lung cancer clinic: Prevalence and predictors of clinically significant

distress. Graves KD, Arnold SM et al. s.l. : Lung Cancer, 2007.

28. A systematic review of the impact of stigma and nihilism on lung cancer outcomes. Chambers SK, Dunn J, et al.

s.l. : BMC Cancer, 2012.

29. Cancer Australia. Best practice approaches to the management of lung cancer in Australia: Final Report. s.l. :

Cancer Australia, 2013.

30. —. The Clinical Practice Guidelines for the Treatment of Lung Cancer. s.l. :

https://wiki.cancer.org.au/australia/Guidelines:Lung_cancer#_ga=2.238687552.1151511378.1512872743-

855478058.1504490775, Accessed December 2017.

31. Lung cancer treatment rates and the role of the lung cancer nurse specialist: a qualitative study. Tod, Angela

Mary et al. s.l. : BMJ Open, 2015, Vols. 5:e008587. doi:10.1136/bmjopen-2015-008587.

32. Senate Select Committee. Select Committee into Funding for Research into Cancers with Low Survival Rates. s.l. :

Commonwealth of Australia, 2017.

33. United Kingdom Lung Cancer Coalition. s.l. : http://uklcc.org.uk/lung-cancer-nurse-specialists/, Accessed Dec

2017.

34. Zwerink, M and al, et. Self management for patients with chronic obstructive pulmonary disease. s.l. :

Conchrane Library, 2014 accessed Dec 2017 at: http://www.cochrane.org/CD002990/AIRWAYS_self-management-

for-patients-with-chronic-obstructive-pulmonary-disease.

35. National Health and Medical Research Council. Research funding and statistics data. s.l. : NHMRC, Accessed

December 2017 at www.nhmrc.gov.au/grants-funding/research-funding-statistics-and-data.

36. Australian Institute of Health and Welfare. Australian Burden of Disease Study: Impact and causes of illness and

deaths in Australia 2011. Canberra : Australian Institute of Health and Welfare, 2016. 2204-4108.


37. Social isolation, loneliness, and all-cause mortality in older men and women. Steptoe A, et al. Berkeley :

Proceedings of the National Academy of Sciences of the United States of America, 2012. Vol. 110.

improving outcomes for australians with lung disease · 2018. 9. 11. · improving outcomes for...

Documents